Choosing a depression treatment could eventually involve measuring how a patient’s brain networks interact before prescribing care. Nature’s recent feature on personalized psychiatry introduces that possibility within a broader vision combining brain scans, biological measurements, and everyday behavioral data.
For depression, the central question is practical: can a measurable brain characteristic help identify which treatment is most likely to work for a particular person?
The evidence offers promising clues. However, identifying a pattern associated with recovery is only the beginning of building a reliable treatment-selection tool.
The Treatment Decision Still Starts With Clinical Assessment
Depression care commonly involves choosing among psychotherapy, medication, and other interventions based on symptoms, treatment history, patient preferences, and clinical circumstances.
These considerations remain essential. Yet they do not consistently reveal whether an individual will respond better to one otherwise appropriate treatment than another.
Brain biomarkers could potentially add information to that decision. Their value would depend on improving outcomes beyond what clinicians and patients can achieve using existing assessments.
How Brain Biomarkers Could Guide Treatment Choice
One study referenced in the Nature feature examined whether brain connectivity could distinguish outcomes with cognitive behavioral therapy, or CBT, versus antidepressant medication.
Researchers analyzed resting-state functional MRI scans from 122 adults with major depressive disorder who completed 12 weeks of randomly assigned treatment in the PReDICT trial.
The participants were treatment-naive, making the study particularly relevant to initial treatment selection. Investigators examined connectivity between the subcallosal cingulate cortex, a region implicated in mood regulation, and other brain areas.
Why Comparing Treatments Matters
A useful treatment-selection biomarker must do more than identify people likely to improve.
It needs to indicate whether one treatment offers a relative advantage over another. Otherwise, a scan might predict general recovery without helping anyone choose care.
By comparing psychotherapy and medication within a randomized trial, the researchers could investigate this more demanding question. However, treatment assignment was randomized, rather than directed by the scan results.
Opposite Connectivity Patterns Tracked Different Outcomes
Connectivity between the subcallosal cingulate and three other regions was associated with different outcomes across treatments.
Positive summed connectivity scores were associated with remission after CBT and treatment failure after medication. Negative scores showed the reverse pattern.
Reported classification rates ranged from 72% to 78% for remission and 75% to 89% for treatment failure. These were research classification results, rather than demonstrated success rates for a clinical scan-guided treatment service.
A Predictive Signal Still Needs Prospective Testing
The findings support investigating brain connectivity as a candidate biomarker. They do not establish that ordering a scan improves a patient’s chance of recovery.
That requires prospective testing: measuring the biomarker first, using it to inform treatment, and determining whether outcomes improve compared with usual decision-making.
Independent validation would also help establish whether the signal holds across different clinics, scanners, and patient populations.
Connectivity Describes Coordination, Not A Proven Cause
Resting-state functional connectivity measures how activity-related signals fluctuate together across brain regions while someone is not performing a specific task.
The underlying hypothesis is that different network configurations may correspond to different capacities to benefit from particular treatments.
However, an association between connectivity and outcome does not prove that the measured connection causes treatment response. A useful predictor and a confirmed biological mechanism are separate scientific achievements.
The Distinction Is Treatment Matching
This research moves beyond asking whether depressed and nondepressed brains differ.
Its more clinically relevant aim is to distinguish between treatment options for someone already seeking help. That focus makes the work relevant to precision psychiatry, while keeping the evidentiary burden clear.
The findings also cannot automatically be extended to TMS, ketamine, or other interventions that this analysis did not compare.
From Research Signal To Better Decisions
For clinics, a future biomarker would need to justify its cost, accessibility, and influence on care. For patients, its purpose should be a better treatment decision with understandable uncertainty.
Brain biomarkers may eventually help personalize depression treatment. The next decisive step is demonstrating that acting on their predictions produces better outcomes.
Citations
- Adam, D. The Grand Plan To Transform Psychiatry — By Personalizing Mental-Health Care. Nature. October 28, 2026.
- Dunlop, B. W., et al. Functional Connectivity Of The Subcallosal Cingulate Cortex And Differential Outcomes To Treatment With Cognitive-Behavioral Therapy Or Antidepressant Medication For Major Depressive Disorder. American Journal of Psychiatry. 2017, 174(6), 533–545.
Explore more at Interventional Psychiatry Network.
